13 research outputs found

    Principal component analysis (PCA) plots built from 128 metabolites detected by GC-MS.

    No full text
    <p>Each point on the scoreplot on the left represents a single sample. The loadings plot on the right depicts metabolites. Points are colored according to the Nugent scoring criteria for diagnosis of bacterial vaginosis (BV), where N = Normal, Int = intermediate and BV = bacterial vaginosis.</p

    Vaginal microbiota at recruitment, after 1 month probiotic or placebo and at birth.

    No full text
    <p>Only subjects who completed the study to birth visits are shown (N = 12). One subject in the placebo group was unable to provide a sample at birth and therefore is not included in the above figure. Nugent scores were not collected for birth visits. N: Normal Nugent Score, Int: Intermediate Nugent Score, BV: Bacterial Vaginosis Nugent Score.</p

    V4 16S sequencing of batch cultured vaginal microbiota in prebiotics

    No full text
    Vaginal microbiota from 4 subjects (2N, BZ, C9, N6) were collectively grown in vaginally-defined medium without glucose (o), or with 0.5% glucose (G), lactitol (tol), lactulose (lose), raffinose (R) or oligofructose (OF). Time points taken for V4 variable region of 16S rRNA sequencing by Illumina MiSeq were 0, 6, 12, 24, and 48 hours after inoculation

    A Systems Biology Approach Investigating the Effect of Probiotics on the Vaginal Microbiome and Host Responses in a Double Blind, Placebo-Controlled Clinical Trial of Post-Menopausal Women

    No full text
    <div><p></p><p>A lactobacilli dominated microbiota in most pre and post-menopausal women is an indicator of vaginal health. The objective of this double blinded, placebo-controlled crossover study was to evaluate in 14 post-menopausal women with an intermediate Nugent score, the effect of 3 days of vaginal administration of probiotic <i>L. rhamnosus</i> GR-1 and <i>L. reuteri</i> RC-14 (2.5Ă—10<sup>9</sup> CFU each) on the microbiota and host response. The probiotic treatment did not result in an improved Nugent score when compared to when placebo. Analysis using 16S rRNA sequencing and metabolomics profiling revealed that the relative abundance of <i>Lactobacillus</i> was increased following probiotic administration as compared to placebo, which was weakly associated with an increase in lactate levels. A decrease in <i>Atopobium</i> was also observed. Analysis of host responses by microarray showed the probiotics had an immune-modulatory response including effects on pattern recognition receptors such as TLR2 while also affecting epithelial barrier function. This is the first study to use an interactomic approach for the study of vaginal probiotic administration in post-menopausal women. It shows that in some cases multifaceted approaches are required to detect the subtle molecular changes induced by the host to instillation of probiotic strains.</p><p>Trial Registration</p><p>ClinicalTrials.gov <a href="http://clinicaltrials.gov/ct2/show/NCT02139839" target="_blank">NCT02139839</a></p></div

    Microbiota heat map.

    No full text
    <p>Each column represents the microbiota of a single sample with the 50 most abundant OTUs displayed with their taxonomies and the remainder pooled. Samples are clustered by the participant of origin and organized from first to last visit from left to right. The time points immediately following administration of the placebo or probiotic are indicated with a blue or green arrow (respectively). OTUs representing the putative OTUs for <i>L. rhamnosus</i> GR-1 and <i>L. reuteri</i> RC-14 have been bolded.</p

    Selected genus relative abundances following probiotic and placebo interventions.

    No full text
    <p>(A) <i>Lactobacillus</i>, (B) <i>Gardnerella</i>, (C) <i>Atopobium</i>, (D) <i>Prevotella</i>, (E) <i>Streptococcus</i>, (F) <i>Staphylococcus</i>. Following probiotic administration for 3 days, the proportion of <i>Lactobacillus</i> is significantly increased while that of <i>Atopobium</i> is decreased and <i>Staphylococcus</i> is increased. Placebo interventions increased <i>Streptococcus</i> and <i>Staphylococcus</i> abundance. *FDR<0.1, **FDR<0.05, ***FDR<0.01.</p

    Summary of Nugent Score Change - Proportion of Improvement from Baseline.

    No full text
    1<p>Improvement in Nugent Score: indicated by shift of intermediate score (4–6) at baseline to normal score (0–3) at follow-up visits. Baseline Nugent score for study Phase-I was collected at visit 3, and baseline Nugent score for study Phase-II was collected at visit 6.</p>2<p><i>p</i>-value is based on McNemars test to determine results of cross-over treatment regimen.</p
    corecore